An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity

FLT3 (FMS-like tyrosine kinase 3), expressed on the surface of acute myeloid leukemia (AML) blasts, is a promising AML target, given its role in the development and progression of leukemia, and its limited expression in tissues outside the hematopoietic system. Small molecule FLT3 kinase inhibitors...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Ther
Main Authors: Yeung, Yik Andy, Krishnamoorthy, Veena, Dettling, Danielle, Sommer, Cesar, Poulsen, Kris, Ni, Irene, Pham, Amber, Chen, Wei, Liao-Chan, Sindy, Lindquist, Kevin, Chin, S. Michael, Chunyk, Allison Given, Hu, Wenyue, Sasu, Barbra, Chaparro-Riggers, Javier, Djuretic, Ivana
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Gene & Cell Therapy 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7054815/
https://ncbi.nlm.nih.gov/pubmed/31981494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2019.12.014
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares